{
    "nctId": "NCT00647075",
    "briefTitle": "Yunzhi as Dietary Supplement in Breast Cancer",
    "officialTitle": "A Randomized, Parallel, Double-blind, Placebo-controlled, Pilot Clinical Study on the Effects of Yunzhi as Dietary Supplement in 60 Adult Patients Undergoing Adjuvant/Neoadjuvant Chemotherapy for Breast Cancer.",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Mean change in signs and symptoms from baseline measured by Visual Analogue Scale (VAS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women with diagnosis of breast cancer\n2. Undergoing adjuvant/neoadjuvant chemotherapy with either FEC, FAC, TAC, or EC + docetaxel combinations.\n3. \u2265 18 years of age\n4. Performance status: 0-2\n5. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Any prior history of yunzhi use\n2. Use of other herbal remedies during the study duration\n3. Significant cardiac, pulmonary, renal, hepatic, gastrointestinal, CNS, psychiatric disease or illicit substance use/abuse that in the opinion of the investigator would make the participant a poor candidate for study participation\n4. Pregnancy (for women of childbearing potential, a negative pregnancy test, urine or serum, is required within 14 days prior to randomization)\n5. Systemic use of progestins, androgens or other steroids (dexamethasone is allowed if used as antiemetic therapy)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}